The Conversation (0)
Bloomberg reported that Merck & Co.’s (NYSE:MRK) experimental insomnia drug, meant to be a less disruptive alternative to Sanofi’s Ambien sleeping pill, is safe only at lower doses, U.S. regulatory advisers said.
Bloomberg reported that Merck & Co.’s (NYSE:MRK) experimental insomnia drug, meant to be a less disruptive alternative to Sanofi’s Ambien sleeping pill, is safe only at lower doses, U.S. regulatory advisers said.
As quoted in the market news:
Merck is seeking Food and Drug Administration approval to sell the treatment, suvorexant, in two dose ranges. The lowest doses of 15 milligrams to 20 milligrams are safe, a panel of advisers to the FDA voted 13-3 yesterday at a meeting in Silver Spring, Maryland. The highest doses of 30 milligrams to 40 milligrams aren’t safe, the panel said in an 8-7 vote.